Synthesis and biological evaluation of new heteroaryl carboxylic acid derivatives as anti-inflammatory-analgesic agents. 2013

Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.

A series of nicotinic acid derivatives structurally related to niflumic acid and certain pyridazine-containing compounds have been synthesized and characterized by analytical and spectral data. All compounds were screened for their potential analgesic and anti-inflammatory activities. The compounds which displayed analgesic and anti-inflammatory activities were tested for ulcerogenicity and screened for in vivo inhibition of certain inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). Compounds 1c, 2a, 2b, and 5a have shown potent analgesic and anti-inflammatory activities.

UI MeSH Term Description Entries
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D009544 Niflumic Acid An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. Donalgin,Flunir,Niflactol,Niflugel,Nifluril,Acid, Niflumic
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004487 Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE. Dropsy,Hydrops,Anasarca
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D014456 Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue. Ulcers

Related Publications

Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
January 2013, Chemical & pharmaceutical bulletin,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
October 2010, Archiv der Pharmazie,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
June 2007, Bioorganic & medicinal chemistry,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
September 2009, Bioorganic & medicinal chemistry letters,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
January 2017, Iranian journal of pharmaceutical research : IJPR,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
February 1976, Journal of pharmaceutical sciences,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
February 2008, Bioorganic & medicinal chemistry letters,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
January 2023, Current drug discovery technologies,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
February 2016, Archiv der Pharmazie,
Khaled Abouzid Mohamed Abouzid, and Nadia Abdalla Khalil, and Eman Mohamed Ahmed, and Sawsan Abo-Bakr Zaitone
April 2014, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!